Wednesday, April 20 Poster Session 8:30 a.m.–7:00 p.m. P5.343 Lack of CerS2 Suppresses the Development of Experimental Autoimmune Encephalomyelitis by Impairing the Migratory Potential of Neutrophils —Christoph Mayer, Julia Barthelmes, Yael Pewzner-Jung, Katja Schmitz, Anika Maenner, Christian Foerch, Max Eberle, Nadja Tafferner, Nerea Ferreiros, Kerstin Birod, Gerd Geisslinger, Anthony Futerman, Sabine Grösch, Susanne Schiffmann, Christine Schuhmann P5.344 The Antibody Response to Epstein-Barr Virus in Multiple Sclerosis Is Increased Only to Selected Antigens — John Lindsey, Matthew Dooley P5.345 IL-17 and IL-22-Secreting Myelin-Specific CD4+ T Cells Corticosteroid Resistant Are Related to Active Brain Lesions in Multiple Sclerosis Patients —Ana Cristina Dos Santos, Joana Hygino, Thais Ferreira, Taissa Kasahara, Priscila Barros, Priscila Sacramento, Regis Andrade, Solange Maria Das Gr Camargo, Fernanda Rueda, Soniza Alves-Leon, Regina Alvarenga, Cleonice Bento, Claudia Cristina Vasconcelos P5.346 Myelin Oligodendrocyte Glycoprotein (MOG) Autoimmunity. A Case Report —Rocio Vazquez do Campo, Ramon Yarza, Sebastian Lopez Chiriboga, Kevin Barrett P5.347 Estrogen Receptor Alpha- Associated Genomic Regions Are Potential Core of T Cell Subtypes Identity —Santina Cutrupi, Marinella Clerico, Ferrero Giulio, Andrea Iannello, Tamaddon Eliseo, Michele De Bortoli, Luca Durelli P5.348 Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity —Marinella Clerico, Santina Cutrupi, Stefania De Mercanti, Simona Rolla, Andrea Iannello, Giulio Ferrero, Michele De Bortoli, Luca Durelli P5.349 CSF Neurofilament Light Chain Levels As a Biomarker for Pediatric Demyelinating Diseases —Soe Mar, Laura Piccio P5.350 Early Identification of Interferon-beta Responders by Assessment of T Cell Lineage-Specific Transcription Factors and Cytokines Expression in Multiple Sclerosis —Mariem Kchaou, Mariem Belguith, Nadia Ben Ali, Khadija Bahrini, Saloua Fray, Ridha Barbouche, Samir Belal Movement Disorders: Parkinson's Disease I P5.351 Patients’ Experience of Parkinson’s Disease Following Treatment with Inhaled Levodopa: Results from a Phase 2b Study —Peter LeWitt, Alexander Niyazov, Alexander Sedkov, Harald Murck, Amy Guo P5.352 Verbal Fluency Trends in Early Stage Parkinsons Disease Patients Following Deep Brain Stimulation: Analysis of Five-Year Extension of a Randomized Pilot Trial —Katherine Panushka, Amanda Currie, Mallory Hacker, Michael Tramontana, Scott Wylie, Peter Konrad, Thomas Davis, Joseph Neimat, Fenna Phibbs, Peter Hedera, David Charles P5.353 MDS Research Criteria for Prodromal Pakrinson's Disease —Ronald Postuma, Daniela Berg P5.354 Antisense Oligonucleotides to LRRK2 Ameliorate Alpha-synuclein Pathology and Behavioral Deficit Induced by Pre-formed Alpha-synuclein Fibrils — Hien Zhao, Tracy Cole, Andreas Weihofen, Eric Swayze, Holly Kordasiewicz P5.355 Patient-Centered Outcomes of Deep Brain Stimulation in Parkinson’s Disease —Jessica Karl, Bichum Ouyang, Leonard Verhagen Metman P5.356 Phenotypic Differences Between African American and Caucasian Parkinson’s Disease Patients —Meagan Bailey, Bichum Ouyang, Glenn Stebbins, Lisa Shulman, Lisa Barnes, Deborah Hall P5.357 The Relationship Between Nutrient Status and Cognitive Performance in Persons with Parkinson’s Disease —Amie Hiller, Charles Murchison, Brenna Cholerton, Shu-Ching Hu, Cyrus Zabetian, James Leverenz, Kathryn Chung, Thomas Montine, Natasha Carney, Joseph Quinn P5.358 Correlates of Parkinsonism in African Americans in Chicago —Deborah Hall, Bichun Ouyang, Joshua Shulman, Lisa Shulman, Lisa Barnes P5.359 Conjugal Parkinsonism in Autopsy Confirmed Cases —Ali Rajput, Christopher Robinson, Leslie Ferguson, Matthew Farrer P5.360 Risk of Parkinson’s Disease in Patients with Diabetes Mellitus and Other Comorbidities in Taiwan —Chia-Ju Lee, Yi-Chun Yeh, Chun-Yu Liang, Yen-Yu Chen P5.361 Levodopa Carbidopa Infusion Gel to Treat Very Advanced Idiopathic Parkinson’s Disease —Jason Aldred, Anne Bergeleen P5.362 Efficacy and Safety of Levodopa-Carbidopa Intestinal Gel from an Open-Label Study in Japanese, Taiwanese, and Korean Patients with Advanced Parkinson’s Disease —Miho Murata, Masahito Mihara, Kazuko Hasegawa, Beomseok Jeon, Chon-Haw Tsai, Masayuki Yokoyama, Krai Chatamra, Janet Benesh P5.363 α-Synuclein Deposition in the Colon and Premotor Markers of Parkinson’s Disease in Neurologically Normal Subjects —Joong-Seok Kim, Su- Young Kim, Won-Kyung Kang P5.364 The Clinical Utility of Sudoscan As a Biomarker for Parkinson's Disease with Lewy Bodies —Inigo Gabilondo, Beatriz Tijero Merino, Amaia Gonzalez, Marian Acera, Veronica Llorens, Jesus Gardeazabal, Maria Rosario Luquin, Mar Carmona, Juan Carlos Gomez Esteban P5.365 The Long and the Short of Survival in Parkinsonism —Leslie Ferguson, Matthew Farrer, Christopher Robinson, Ali Rajput P5.366 Effect of Vibration on Motor Performance: A New Intervention to Improve Bradykinesia in Parkinson’s Disease? —Antonella Macerollo, Clare Palmer, Thomas Foltynie, Prasad Korlipara, Patricia Limousin, Mark Edwards, James Kilner P5.367 7,8-DHF Ameliorates L-DOPA- Induced Dyskinesia in a Parkinson’s Disease Rat Model —Junyan Zhao, Ti-Li Zhen, Hai-Yang Shu, Meng Si, Chunfeng Liu, Li-fang Hu, Yi-Xian Huang, Wei-Feng Luo P5.368 Higher LDL-Cholesterol Is Associated with Higher Gyrification During Parkinson's Disease Progression — Nicholas Sterling, Eun Lee, Mechelle Lewis, Guangwei Du, Martin Styner, Lan Kong, Richard Mailman, Xuemei Huang P5.369 Interaction of Stretch Reflex Loop with Descending B-Oscillations and the Generation of Tremor in Parkinson’s Disease: A Study of Motor Unit Firing Synchrony and Patterns —Orsalia M. Agapaki, Dimitrios Anastasopoulos, Sophia Erimaki, Constantinos N. Christakos P5.370 GAITRite Comparison Between Parkinson's Disease Stages —Wissam Deeb, Daniel Martinez-Ramirez, Juan Giugni, Michael Okun, Chris Hass P5.371 Genetic Etiology of Early- Onset Parkinsonism in Norway —Emil Gustavsson, Joanne Trinh, McKenzie Marna, Stephanie Bortnick, Matthew Farrer, Jan Aasly P5.372 Effect of Patient Characteristics on Motor Function in Response to 35-50 Mg of Inhaled Levodopa (CVT-301) in Patients with Parkinson’s Disease: Results from a Phase 2b Study —Peter Lewitt, Martin Freed, Mika Leinonen, Alexander Sedkov, Harald Murck P5.373 Amantadine Alleviates the Motor and Dopamine Receptor Changes in a Levodopa-Induced Dyskinesia (LID) Model of C. Elegans —Allison Kao, Ruifu Liu, Deepak Gupta, Zhaoyang Feng P5.374 Effect of Fatigue on Physical Versus Mental Health-Related Quality of Life in Parkinson Disease —Laura Brosbe, Ann Gruber-Baldini, Erik Barr, F. Rainer Von Coelln, Stephen Reich, Lisa Shulman P5.375 Olfaction, Attention Performance, and Response Speed Variability in Early Parkinson’s Disease — Magdalena Wojtowicz, Kimberly Good, Roger McKelvey, Harold Robertson, John Fisk P5.376 Weight Changes in PD Patients Post-DBS: A Look at the Factors Involved —Bilal Ahmed, Leonardo Almeida, Alberto Bona, Sol De Jesus, Daniel Martinez- Ramirez, Michael Okun P5.377 Advanced Therapy Referral in Parkinson’s Disease Using Wearable Sensors —Dustin Heldman, Joseph Giuffrida, Esther Cubo Delgado P5.378 Can Transcranial Magnetic Stimulation Improve Axial Symptoms in Parkinson’s Disease? —Milton Biagioni, Andre Son, Alberto Cucca, Katherine Sticklor, Shashank Agarwal, Geraldine Dacpano, Miroslaw Brys, Franziska Battenberg, Jamika Singleton-Garvin, Pawan Kumar, Rebecca Gilbert, Angelo Quartarone, Alessandro Di Rocco P5.379 Comparing Effects of Age of Onset and Disease Duration in Parkinson Disease —Karl Maki, Ann Gruber-Baldini, Erik Barr, F. Rainer Von Coelln, Stephen Reich, Lisa Shulman P5.380 Success of Targeting Rationale in Deep Brain Stimulation for Parkinson’s Disease —Andra Farcas, Joohi Jimenez Shahed P5.381 Loss-of-Function Mutations of Cyclic Nucleotide Gated (CNG) Ion Channels Protect Dopaminergic Neurodegeneration and Loss of Motor Activity in C. Elegans Overexpressing Human α-Synuclein —Allison Kao, Ruifu Liu, Deepak Gupta, Zhaoyang Feng P5.382 Activation of Chaperone- Mediated Autophagy Prevents Accumulation of Oligomeric Alpha- Synuclein in LRRK2 R1441G Knockin Mice of Parkinson’s Disease —Shu Leong Ho, Philip Wing-Lok Ho, Shirley Pang, Huifang Liu, Colin Siu-Chi Lam, Matthew Chi-Ting Leung, Lingfei Li, David Ramsden P5.383 Statin Usage in Parkinson’s Disease in Relation to Vascular Comorbidities and Risk Factors —Kelvin Cheng, Diane Swallow, Katherine Grosset, Donald Grosset Movement Disorders: Ataxia P5.384 Repeat Size and X-Inactivation in the Clinical Phenotype of Fragile X Premutation Carrier Sisters: A Familial Case Series —Erin Robertson-Dick, Joan O'Keefe, Andrew Hadd, Lili Zhou, Elizabeth Berry-Kravis, Deborah Hall P5.385 The Role of Antisense FMR1 in Fragile X-Associated Tremor/Ataxia Syndrome —Padmaja Vittal, Shrikant Pandya, Elizabeth Berry-Kravis, Lili Zhou, Kevin Sharp, Deborah Hall P5.386 Predictors of Cognitive Decline in FXTAS —Joash Lazarus, Lisa Shubeck, Emily Allen, Debra Hamilton, Jennifer Choi, Stephanie Sherman, Jorge Juncos P5.387 Long-Term Effect of Epoetin Alfa on Clinical and Biochemical Markers in Friedreich Ataxia —Francesco Sacc, Giorgia Puorro, Angela Marsili, Antonella Antenora, Chiara Pane, Carlo Casali, Christian Marcotulli, Giovanni Defazio, Daniele Liuzzi, Chiara Tatillo, Donata Cambriglia, Giuseppe Schiano di Cola, Luigi Giuliani, Vincenzo Guardasole, Andrea Salzano, Antonio Ruvolo, Anna De Rosa, Antonio Cittadini, Giuseppe De Michele, Alessandro Filla P5.388 EPI-743 for Friedreichs Ataxia Patients with Point Mutations —Kelly Sullivan, Mary Freeman, Jessica Shaw, Clifton Gooch, Yangxin Huang, Matthew Klein, Guy Miller, Theresa Zesiewicz P5.389 Difficulties in Making an Antemortem Diagnosis of Sporadic Fatal Insomnia, a Rare Form of Sporadic Prion Disease —Paul Lee, Sandra Camelo-Piragua, Ignazio Cali, Mark Cohen, Vikram Shakkottai 120 2016 AAN Annual Meeting Abstract Listing
Presenters Stand by Posters 5:30 p.m.–7:00 p.m. P5.390 Co-Existence of Novel KIF1A Mutation (SPG30) and Intronic Expansion of BEAN (SCA31) in a Family: Clinical and Genetic Characterization —Arika Hasegawa, Ryoko Koike, Akio Kawakami, Kishin Koh, Yoshihisa Takiyama, Takeshi Ikeuchi P5.391 Novel CACNB4 Variant Associated with a Case of Progressive Ataxia —Alexandra Lloyd-Smith, Shyamal Mehta, Sian Spacey P5.392 X-linked Spinocerebellar Ataxia (SCA) Type 1A: a Novel Late Onset Phenotype of the ATP2B3 Mutation — Christopher Stephen, Kathleen Sweadner, John Penniston, Jeremy Schmahmann P5.393 Neuropathology of Parkinsonism in Spinocerebellar Ataxia Type 6: a Case Report —Diviya Kaul, Keith Morley, Marius Pakalniskis, William Hickey, Stephen Lee Movement Disorders: Ataxia and Dystonia P5.394 A Mutation Causing Reduced BK Channel Activity Leads to Cognitive Inpairment and Progressive Cerebellar Ataxia —Julia Staisch, Xiaofei Du, Joao Carvalho-de-Souza, Tomoya Kubota, Francisco Bezanilla, Christopher Gomez P5.395 49 Year Old Male with Rapidly Progressive Cerebellar Ataxia Secondary to Non-Paraneoplastic Voltage-Gated Calcium Channel Antibodies (VGCC): Case Report —Shnehal Patel, Ilia Itin P5.396 Prolonged Cerebellar Syndrome After Legionnaire’s Disease — Brandon Barton P5.397 The Broadening Clinical Spectrum Associated with ATP1A3 Mutations —Inge Meijer, Naomi Lubarr, Paul Greene, Steven Frucht, Deborah Raymond, William Severt, Vicki Shanker, Rivka Sachdev, Susan Bressman, Laurie Ozelius, Rachel Saunders-Pullman P5.398 Likely Underrecognized Mosaicism in Genetic Disease: High Frequency of Mosaic Mutations in ADCY5-Related Dyskinesia —Dong-Hui Chen, Jennifer Friedman, Aurélie Méneret, Emily Bonkowski, Fuki Hisama, Marie Davis, Phillip Swanson, Saunder Bernes, Marie Vidailhet, Emmanuel Roze, Thomas Bird, Wendy Raskind P5.399 Clinical Characteristics and Natural History of Oromandibular and Lingual Dystonia —Laura Scorr, Stewart Factor, H. Jinnah P5.400 Functional Dystonia: 10-year Experience in a Specialized Dystonia Clinic —Christopher Stephen, David Perez, Nutan Sharma P5.401 The Role of Acetyl-L-Carnitine Levels and 95A>G Mutations in the SLC22A5 Gene on Parkinson’s Disease in Faroe Islands —Maria Skaalum Petersen, Jónrit Halling, Debes Christiansen, Sára Bech P5.402 Preclinical Model of Parkinson’s Disease Using Circuit Specific Optogenetics —Neel Patel, Vishakh Iyer, Kala Venkiteswaran, Erin Handly, Caitlin White, Naila Iqbal, Pooja Sridhar, Kedar Thiagarajan, Zhiwen Liu, Charu Ramakrishnan, Karl Deisseroth, Thyagarajan Subramanian Frequently Asked Questions Wed· April 20 Do I need to register for the Annual Meeting courses that I want to take? No. A big change this year is that most courses no longer require pre-registration. You are free to attend any course you like. Courses that require pre-registration are clearly marked. How do I plan my Annual Meeting schedule? The Annual Meeting Mobile App and Itinerary Planner (available within the registration site) are optional tools available to assist you in customizing your itinerary. You can edit your itinerary at any time; adding course(s) or event(s) to your schedule does not require you to attend. During the meeting, you are free to move between sessions, as you wish. We only ask that you are mindful of the speakers and other attendees and enter and exit with as little disruption as possible. How can I guarantee that I have a seat in a particular session? The sessions that do not require pre-registration are first-come, first-serve seating. Please arrive early to any session(s) that you must attend. Full session(s) may be overflowed to a second room. How can I access my course syllabi? New for 2016, all attendees will receive complimentary online access to all Annual Meeting Syllabi for one year. Notifications will be sent out prior to the meeting with instructions for access. Attendees may choose to upgrade to a USB drive for permanent access. Fast and easy registration · AAN.com/view/AM16 121